GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (STU:AT2) » Definitions » Cyclically Adjusted Price-to-FCF

Atara Biotherapeutics (STU:AT2) Cyclically Adjusted Price-to-FCF : (As of May. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Atara Biotherapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Atara Biotherapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Atara Biotherapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Cyclically Adjusted Price-to-FCF Chart

Atara Biotherapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Atara Biotherapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Atara Biotherapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Atara Biotherapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atara Biotherapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's Cyclically Adjusted Price-to-FCF falls into.



Atara Biotherapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Atara Biotherapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Atara Biotherapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.195/131.7762*131.7762
=-0.195

Current CPI (Mar. 2024) = 131.7762.

Atara Biotherapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.177 100.560 -0.232
201409 -0.164 100.428 -0.215
201412 -0.206 99.070 -0.274
201503 -0.279 99.621 -0.369
201506 -0.230 100.684 -0.301
201509 -0.416 100.392 -0.546
201512 -0.376 99.792 -0.497
201603 -0.421 100.470 -0.552
201606 -0.358 101.688 -0.464
201609 -0.494 101.861 -0.639
201612 -0.726 101.863 -0.939
201703 -0.748 102.862 -0.958
201706 -0.713 103.349 -0.909
201709 -0.727 104.136 -0.920
201712 -0.955 104.011 -1.210
201803 -1.119 105.290 -1.400
201806 -0.904 106.317 -1.120
201809 -0.993 106.507 -1.229
201812 -1.182 105.998 -1.469
201903 -1.362 107.251 -1.673
201906 -1.055 108.070 -1.286
201909 -0.887 108.329 -1.079
201912 -0.958 108.420 -1.164
202003 -1.011 108.902 -1.223
202006 -0.767 108.767 -0.929
202009 -0.559 109.815 -0.671
202012 -0.045 109.897 -0.054
202103 -0.624 111.754 -0.736
202106 -0.573 114.631 -0.659
202109 -0.571 115.734 -0.650
202112 -0.334 117.630 -0.374
202203 -0.785 121.301 -0.853
202206 -0.607 125.017 -0.640
202209 -0.643 125.227 -0.677
202212 -0.521 125.222 -0.548
202303 -0.349 127.348 -0.361
202306 -0.468 128.729 -0.479
202309 -0.455 129.860 -0.462
202312 -0.428 129.419 -0.436
202403 -0.195 131.776 -0.195

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Atara Biotherapeutics  (STU:AT2) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Atara Biotherapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics (STU:AT2) Business Description

Traded in Other Exchanges
Address
2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (STU:AT2) Headlines

No Headlines